For example, our Cardiovascular Unit found that, despite the fact that the plasma levels of C-reactive protein (CRP) are considered a biomarker in CAD and are related to outcome and prognosis, a Mendelian randomization study determined that these levels were not causal and, therefore, CRP has not be considered a potential drug target for the treatment of CAD [50,59]. Here, CRP is linked to coronary artery disorder.